Curapath is a new, bigger vision for our future. We will have the same great services and an even better look! Watch this space for the upcoming transition.
What we do
PTS is a technology-focused company specializing in the design and manufacturing of nanoparticle delivery systems leveraging our technical expertise in custom polymer, lipid, and polyamino acid synthesis. PTS’s capabilities support our partner’s therapeutic programs from discovery, clinical development, and product commercialization.
PTS is a leader in the Design, Development & Custom Manufacturing of Drug Substances (DS) and Drug Products (DP) related to advanced drug delivery systems. Our company provides a comprehensive CMC package, including Preclinical Development, Technology Transfer, cGMP Manufacturing and aseptic Fill & Finish.
Services
Polyamino Acid Design & Functional Proof of Concept
Our team will provide your team an extensive knowledge on polymer-biology interface to design technologies specially suited for delivering Nucleic Acids, Small Drugs and Proteins.
Process Development & Preclinical Batches
Flexible and agile approach to develop robust and reproducible processes to meet your specific product requirements for GLP TOX studies.
GMP production & regulatory support
We offer an integral solution to bring your developments from preclinical to GMP manufacturing including our support on regulatory affairs & CMC-DMF documentation.
Analytical Development & QC
Our QC scientists support the development of Drug Substances through the entire project life-cycle within GMP & GLP Certified Lab and qualified equipment. Equipment and skills are specially suited but not limited to method development, validation and stability studies.
Testimonials
Ruben Herrendorff
CEO at Polyneuron Pharmaceuticals
PTS has been a very valuable and reliable CMO partner for the past 3 years. The team is very supportive, solution-oriented and dedicated, always willing to go the extra mile to provide excellent results on time. We have been appreciating the tangible long-term vision and value-creating mindset that this company has.
Daniel J. Huang & Michael P. Bevilacqua
Vice President of Operations & M.D., Ph.D. - CEO, CSO, Director & Co-Founder on AMICROBE
PTS has proven itself to be a capable and reliable partner. Over the past two years, we have been repeatedly impressed by their knowledge and professionalism. The PTS team has been both skilled and responsive to our needs, as well as innovative in meeting new challenges. Simply stated, PTS has brought real value to our programs and to our company. We look forward to the next phases of our relationship.
Professor Tim J. Deming
Bioengineering Department - Chemistry and Biochemistry Department at University of California Los Angeles
I have been fortunate to work with PTS on a number of projects where they have been an excellent partner as a CMO and fantastic team members in research and development activities. Having worked in the polypeptide field for more than 25 years, I have seen and been involved with many efforts to commercialize these specialty polymers. In my view, PTS has achieved a depth of understanding and a level of expertise in polypeptide manufacturing and analytics that is second to none. I see PTS as a tremendous asset to the polypeptide community, and highly recommend them as a valuable resource for all polypeptide manufacturing needs
Samaridou Eleni, PostDoctoral Researchar & Jose Crecente, Research Scientist
Dept. of Pharmacy and Pharmaceutical Technology, USC CIMUS Research Institute
Working with PTS on the development of novel polymers for our nanosystems was really profitable. Their expertise in the field of polymer synthesis and characterization enabled us to conduct state-of-the-art research. It is worth mentioning that PTS personnel efficiently supported us with their knowledge at all stage of our collaboration, while timely and successfully completed their tasks. Taking into account everything above, we would be happy to collaborate again with them.
DR. THOMAS BRUCKDORFER
CSO & VP BUSINESS DEVELOPMENT,
IRIS BIOTECH GMBH, GERMANY
We have found with PTS a partner, who has profound and deep know-how in both technical aspects of developing and manufacturing real innovative carriers in the field of polymer therapeutics and furthermore a deep understanding for the administrative and documentation necessities in the pharma world. Both is extremely important and valuable, as new developments in the field of biopharmaceuticals require a solid technical understanding from chemistry to pharmacology to biochemistry and medicinal chemistry, as well as the special regulatory aspects, which have to be matched by any party acting in the health industry.
DR. BEATRIU ESCUDER
ASSOCIATE PROFESSOR, HEAD OF THE BIOSUPRAMAT RESEARCH GROUP
Filling the gap between academia and industry is a big challenge. PTS is an ideal partner for application-oriented academic research in order to transfer fundamental research into the market. PTS research team possess a high level of training in scientific research combined with a privileged vison of the societal needs.
News
Proyecto de inversión INPYME 2022
Polypeptide Therapeutic Solutions, S.L. ha llevado a cabo en 2022 un importante proyecto de inversión subvencionado con 41.164,48 € por la Conselleria d’Economia Sostenible, Sectors Productius, Comerç i Treball a través del expediente INPYME/2022/1009 dentro de la convocatoria de ayudas INPYME 2022. Con la subvención de:
Polypeptide Therapeutics Solutions (PTS) Announces Company Name Change to Curapath and Expansion of Drug Delivery Capabilities and Services
Expanded capabilities support development and production of novel functional lipid excipients and nanoparticle formulation Addition of late stage clinical and commercial-scale production is also planned Company to present on shielding lipid novel excipients for lipid nanoparticle (LNP) formulations at Lipid Nanoparticles Development Summit on October 20th Valencia, Spain and Boston, MA, October 17, 2022 –…
Proyecto CDTI: Investigación de una nueva vacuna para una enfermedad respiratoria humana
Hipra Scientific S.L.U, Polypeptide Therapeutic Solutions S.L., Biotechvana S.L. y Nostrum Biodiscovery constituyen el consorcio de empresas que participan en el proyecto “Investigación de una nueva vacuna para una enfermedad respiratoria humana”, subvencionado por el CDTI (Centro para el Desarrollo Tecnológico Industrial), apoyado por el Ministerio de Ciencia e Innovación y financiado por la Unión Europea…
Events
Contract Pharma
The 21st Annual Contracting & Outsourcing Conference & Tabletop Exhibition will be held September 22-23, 2022 at Hyatt Regency New Brunswick, NJ, located in the heart of New Jersey’s pharmaceutical industry. The two-day conference and one-day exhibition on September 22nd provides the perfect venue for easy, informal discussions for manufacturing, packaging, laboratory services and more! The tabletop exhibition will be…
European LNP
The LNP Development Europe Summit is the only European conference solely dedicated to LNP formulation and process development to enable seamless scale-up, keeping GMP compliance and manufacturing in mind. Given the rapid developments in the field and the success of Pfizer / BioNTech’s mRNA vaccine, lipid nanoparticles have finally reached an inflection point. With new technologies and advancements, LNPs are now a commercially viable delivery vehicle with clinical utility. We have…
Next Generation LNPs
The Next Generation Lipid-Based Nanoparticles Delivery Summit is your definitive industry-led meeting to design and engineer 2nd generation of lipid nanoparticles for emerging payloads beyond RNA into clinic. Join Intellia Therapeutics, Entos Pharmaceuticals, AstraZeneca, Eli Lilly, and other scientific trailblazers as they navigate the next generation of lipid-based nanoparticles for targeted delivery to expedite innovative treatments for unmet patient needs.
CRS 2022
The conference theme this year is “Advanced Delivery Science”, which reflects their focus on cutting-edge research and innovation across our strong discipline that will keep you up-to-date with new science and inspire new ideas. Most importantly, this event will offer you the ability to meet in-person for the first time since 2019, to network, form…
DDF Summit
The 2022 Summit covers small molecules and biologics, new technologies, concepts and case studies in areas such as: Formulation design for poorly soluble compounds The potential of nanotechnology for better deliverability The latest controlled released technologies Improving patient compliance by harnessing data and the latest smart device technology Optimising formulations for continuous manufacturing Overcoming the blood brain barrier and challenges in oral delivery of biologics Reformulation and biosimilars